BioSpace News Archive

Tonix Pharmaceuticals Holding Corp. announced that in the currently-enrolling Phase 3 study of Tonmya®* for the treatment of posttraumatic stress disorder, the timing of the primary endpoint analysis has been changed from Week 4 to Week 12 and the Company plans to add an interim analysis that allows for a potential sample size adjustment, based on guidance from its recent Breakthrough Therapy Type B Clinical Guidance meeting with the U.S. Food and Drug Administration.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees options to purchase an aggregate of 217,500 shares of BioCryst common stock on October 31, 2019 as inducements material to each employee entering into employment with BioCryst.

FibroGen, Inc., announced that financial results for the third quarter 2019 will be released after market on Monday, November 11, 2019.

Plus Therapeutics, Inc. announced that it will report its Fiscal 2019 Third Quarter financial results after the close of market on November 14, 2019.

Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, provides a business update and reports financial results for the third quarter ended September 30, 2019.

Purchase Price of $30.75 Per Share in Cash; Total Enterprise Value of Approximately $5.4 Billion and Total Equity Value of Approximately $4.7 Billion

Bausch Health Companies Inc. announced its third-quarter 2019 financial results.

3-year corporate partnership will raise $10 million to support Alzheimer’s Association Mission, Campaign will help connect caregivers to resources and support services

Development of PEGPH20 to be Discontinued Immediately

Agenus Inc., an immuno-oncology company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1, and cancer vaccines provided a corporate update and reported financial results for the third quarter of 2019.